1. Prophylaxis Strategies in Hereditary Angioedema Weighing the Evidence

3. This program will include a discussion of investigational agents not yet approved by the FDA for use in the United States. There will also be a discussion of data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

4. Hereditary Angioedema Due to C1-INH Deficiency

5. Short-Term Prophylaxis Treatment Options for Patients With HAE

6. Need for On-Demand Treatment With Short-Term Prophylaxis

7. Decision to Use Long-Term Prophylaxis

8. Long-Term Prophylaxis Attenuated Androgens

9. Physician Survey on Current Trends in Long-Term HAE Prophylaxis Use

10. Long-Term Prophylaxis Plasma-Derived C1-INH Concentrate*

11. Long-Term Prophylaxis Plasma-Derived C1-INH Concentrate

12. Frequency of Peripheral Vein Difficulties Over Past 6 Months

13. Long-Term Prophylaxis Antifibrinolytic Agents

14. Individualizing Treatment Plans for Patients Who Have HAE

16. COMPACT Study Number of HAE Attacks per Month

17. COMPACT Study Secondary Endpoints and AEs

18. Abstracts from AAAAI 2017

19. Emerging Agents for Prophylactic Use*

20. Ongoing Preclinical Research*

21. Concluding Remarks

22. Abbreviations